TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14989442

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 5 ppm
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 70
Study: 11228294

Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry (GDx)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Nerve Fiber Layer (NFL) photographs
Number of subjects: 253

Group type: COMPARATOR
Intervention: Humphrey 24-2 test
Number of subjects: 253
Study: 9758292

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 or 200 mg
Number of subjects: 1474

Group type: COMPARATOR
Intervention: Comparator (500 or 1000 mg amoxicillin, or 625 mg amoxicillin/clavulanic acid)
Number of subjects: 1474
Study: 7798463

Group type: EXPERIMENTAL
Intervention: Simulated exclusion criteria (borderline personality disorder, drug/alcohol dependence, and others)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclics
Number of subjects: 0
Study: 2468049

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29271486

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 0
Study: 28817141

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with butyl-cyanoacrylate (BC) adhesive (PRF group; n = 42)
Number of subjects: 125

Group type: COMPARATOR
Intervention: BC adhesive alone (BC group; n = 42)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sterile wet gauze compression (WG group; n = 41)
Number of subjects: 125
Study: 26888806

Group type: EXPERIMENTAL
Intervention: rhBNP administration (1.5 µg/kg bolus intravenous injection followed by 0.0075-0.03 µg·kg(‐1)·min(‐1) for up to 120 hours)
Number of subjects: 93

Group type: COMPARATOR
Intervention: NIT treatment (10-100 µg/min intravenous infusion for 120 hours)
Number of subjects: 93
Study: 23963331

Group type: EXPERIMENTAL
Intervention: G‐CSF (135 µg/kg body weight intravenous over 72 hours)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 328
Study: 21406015

Group type: EXPERIMENTAL
Intervention: NovoTwist needle
Number of subjects: 120
Study: 18326136

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol and remifentanil (Group R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced inhalational anaesthesia with isoflurane (Group F)
Number of subjects: 40
Study: 16612457

Group type: EXPERIMENTAL
Intervention: Prone position (PP) for three-hour periods
Number of subjects: 41
Study: 14667874

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 66

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 66

Group type: COMPARATOR
Intervention: Spontaneously conceived
Number of subjects: 66
Study: 11712430

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (90 healthy people)
Number of subjects: 30
Study: 8869763

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pupillometric study with morphine
Number of subjects: 0
Study: 1290604

Group type: EXPERIMENTAL
Intervention: Dentin bonding agents (8 different types)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Unfilled resin
Number of subjects: 135
Study: 6427027

Group type: COMPARATOR
Intervention: Clomiphene citrate alone (50 mg/day, cycle days 5 to 9)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus human menopausal gonadotropin (2 ampules/day, cycle days 6, 8, and 10)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus human menopausal gonadotropin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 34
Study: 31132346

Group type: EXPERIMENTAL
Intervention: Complete CHOICE
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Enhanced Care
Number of subjects: 1008
Study: 30168626

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 27194023

Group type: COMPARATOR
Intervention: QRS duration <120 ms
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: QRS duration ≥120 ms
Number of subjects: 3754

Group type: COMPARATOR
Intervention: Normal QRS morphology
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: Non-LBBB QRS morphology
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: LBBB QRS morphology
Number of subjects: 3754
Study: 25283499

Group type: EXPERIMENTAL
Intervention: Telbivudine preemptive therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antiviral therapy
Number of subjects: 60
Study: 22404442

Group type: EXPERIMENTAL
Intervention: LA-CT (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + tetracycline 500 mg q.i.d. for 2nd week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: LA-CM (lansoprazole 30 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week, followed by lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + metronidazole 500 mg t.i.d. for 2nd week)
Number of subjects: 200
Study: 20569670

Group type: EXPERIMENTAL
Intervention: Immunization with Aβ42
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vaccinated case
Number of subjects: 8
Study: 18080055

Group type: COMPARATOR
Intervention: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Delayed-release oral mesalamine 2.4 g/day (400 mg tablet) in moderate disease subgroup
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) in moderate disease subgroup
Number of subjects: 301
Study: 15841784

Group type: EXPERIMENTAL
Intervention: Written information provided in advance
Number of subjects: 169

Group type: COMPARATOR
Intervention: No written information provided (control)
Number of subjects: 169
Study: 11341495

Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9749223

Group type: EXPERIMENTAL
Intervention: Angioplasty (group 2: 1994-1995)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Angioplasty (group 1: 1990-1991)
Number of subjects: 873
Study: 7861799

Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain threshold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of pain threshold to shock intensity and total aggression
Number of subjects: 0
Study: 2518857

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg o.m.)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 181
Study: 412995

Group type: EXPERIMENTAL
Intervention: Combination of glucose, fructose and xylitol (1:2:1 ratio)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 24
Study: 31069922

Group type: EXPERIMENTAL
Intervention: Hypoglycemia in patients with dementia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of dementia after hypoglycemia
Number of subjects: 0
Study: 27958765

Group type: EXPERIMENTAL
Intervention: EMD/BC
Number of subjects: 52

Group type: COMPARATOR
Intervention: EMD alone
Number of subjects: 52
Study: 27089154

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (n = 22)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (n = 9)
Number of subjects: 31
Study: 24151119

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2 mmol/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.2 mmol/kg)
Number of subjects: 15
Study: 22498181

Group type: EXPERIMENTAL
Intervention: e‐counselling (≥ 8 messages)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Waitlist control (0 messages)
Number of subjects: 387
Study: 19412196

Group type: EXPERIMENTAL
Intervention: biologic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: new DMARDs
Number of subjects: 0
Study: 17898955

Group type: EXPERIMENTAL
Intervention: Chinese herbs combined with acupuncture (CH‐A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional treatment (oral intake of vitamin C and E, external application of quban powder)
Number of subjects: 61
Study: 15259826

Group type: EXPERIMENTAL
Intervention: TAU plus CBT
Number of subjects: 90

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 90
Study: 12018882

Group type: EXPERIMENTAL
Intervention: Awakened by AMI symptoms
Number of subjects: 3309

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 3309

Group type: EXPERIMENTAL
Intervention: Low ejection fraction
Number of subjects: 3309
Study: 10463555

Group type: EXPERIMENTAL
Intervention: Health promotion intervention consisting of a review of the child's medical record, explanation of future well-child visits, discussion of the role of the PCP, and a follow-up appointment prior to discharge from the PED.
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 195
Study: 7756226

Group type: EXPERIMENTAL
Intervention: Active treatment with 2.7 g of MaxEpa daily (1.62 g of eicosapentaenoic acid and 1.08 g of docosahexaenoic acid)
Number of subjects: 233
Study: 2156885

Group type: EXPERIMENTAL
Intervention: Leuprolide alone for 5-6 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6996793

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 99
Study: 30661093

Group type: EXPERIMENTAL
Intervention: Endometrial injury
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no endometrial injury)
Number of subjects: 51
Study: 28390649

Group type: EXPERIMENTAL
Intervention: Wound Clamp (WC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Skin Suture (SS)
Number of subjects: 10
Study: 25762759

Group type: EXPERIMENTAL
Intervention: Computerized motivational feedback at baseline, 3 months, and 6 months; 12 weeks of cessation counseling and nicotine patches
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (self‐help guide and brief cessation advice)
Number of subjects: 60
Study: 24029622

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM) group earning one draw per call from a prize bowl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed dollar CM group earning $1 for each call
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups received abstinence rewards according to a high-value voucher incentive schedule confirmed by urine testing
Number of subjects: 0
Study: 22463614

Group type: EXPERIMENTAL
Intervention: Transfusion of red blood cells
Number of subjects: 237

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: sPLA2 threshold level ≥ 48 ng/ml
Number of subjects: 237
Study: 20817936

Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Vision plus exercise
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Multi-component interventions (exercise, vision, home hazard reduction)
Number of subjects: 1090
Study: 17197464

Group type: EXPERIMENTAL
Intervention: 90 degrees angle, forward camber
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 90 degrees angle, reverse camber
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 60 degrees angle, forward camber
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 60 degrees angle, reverse camber
Number of subjects: 200
Study: 16192584

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 348
Study: 11984215

Group type: EXPERIMENTAL
Intervention: Atorvastatin (A) 20 mg/day
Number of subjects: 675

Group type: COMPARATOR
Intervention: Pravastatin (P) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Number of subjects: 675

Group type: COMPARATOR
Intervention: Simvastatin (S) 20 mg/day + Gemfibrozil (G) 1200 mg/day
Number of subjects: 675

Group type: COMPARATOR
Intervention: Pravastatin (P) 20 mg/day + Ciprofibrate (C) 100 mg/day
Number of subjects: 675

Group type: COMPARATOR
Intervention: Simvastatin (S) 20 mg/day + Ciprofibrate (C) 100 mg/day
Number of subjects: 675
Study: 9534678

Group type: EXPERIMENTAL
Intervention: Ultrasonic enhancement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test card procedure
Number of subjects: 0
Study: 7616842

Group type: EXPERIMENTAL
Intervention: High-fiber meals (HF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fiber meals (LF)
Number of subjects: 10
Study: 2375883

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1500 mg d‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 497093

Group type: EXPERIMENTAL
Intervention: Sustained-release oral procainamide preparation 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained-release oral procainamide preparation 2
Number of subjects: 10
Study: 30910320

Group type: EXPERIMENTAL
Intervention: β blockers (propranolol up to 160 mg twice a day or carvedilol ≤25 mg/day)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 201
Study: 29135115

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3mg/kg, administered with short 30-min i.v. infusion every 3 weeks, total of 4 doses
Number of subjects: 89
Study: 26320827

Group type: EXPERIMENTAL
Intervention: Modafinil 300mg daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 23384300

Group type: EXPERIMENTAL
Intervention: Esmolol (0.05 mg·kg(‐1) ·min(‐1) after tracheal intubation, 0.3 mg·kg(‐1) ·min(‐1) during CPB, 0.03‐0.05 mg·kg(‐1) ·min(‐1) until the end of surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30
Study: 20938439

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) (1.2 g per day) for 12 weeks
Number of subjects: 417

Group type: COMPARATOR
Intervention: High-SFA diet
Number of subjects: 417

Group type: COMPARATOR
Intervention: High-monounsaturated fatty acids diet
Number of subjects: 417

Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with placebo
Number of subjects: 417
Study: 19994586

Group type: EXPERIMENTAL
Intervention: Superfine dispersed beta-1,3-glucan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17224858

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/day initially, increased to 20 mg/day after 1 week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Citalopram + HT (10 mg/day initially, increased to 20 mg/day after 1 week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo + HT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Citalopram + HT
Number of subjects: 100
Study: 16595221

Group type: EXPERIMENTAL
Intervention: 0.15 mg of desogestrel plus 0.030 mg of ethinyl E2 daily for 12 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 mg of cyproterone acetate plus 0.035 mg of ethinyl E2 daily for 12 months
Number of subjects: 36
Study: 12883329

Group type: COMPARATOR
Intervention: Oxygen administration for 1 hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11023928

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/d for 3 days and then 500 mg/wk for 3 months
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 9273524

Group type: EXPERIMENTAL
Intervention: Discontinuation of intravenous opiate injections and administration of methadone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continued injecting drug use (Control group)
Number of subjects: 43
Study: 1642909

Group type: EXPERIMENTAL
Intervention: Extradural clonidine 25 micrograms h‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extradural clonidine 50 micrograms h‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose extradural morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of morphine and clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extradural clonidine groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 6518665

Group type: EXPERIMENTAL
Intervention: alpha‐methyldopa (A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: clonidine hydrochloride (C)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both groups (C and A)
Number of subjects: 95
Study: 30795978

Group type: EXPERIMENTAL
Intervention: Diary authored by a close relative
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no diary)
Number of subjects: 75
Study: 30169407

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sugammadex 4 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg and Sugammadex 4 mg/kg
Number of subjects: 50
Study: 28370208

Group type: EXPERIMENTAL
Intervention: Orthorexia nervosa (ON)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Anorexia nervosa (AN)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Bulimia nervosa (BN)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Binge-eating disorder (BED)
Number of subjects: 505
Study: 25424049

Group type: EXPERIMENTAL
Intervention: 10% benzocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 20
Study: 23150144

Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg on 2 consecutive days each month (2CDM)
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Risedronate 5 mg daily
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg 2CDM
Number of subjects: 1229
Study: 21496415

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) at a daily dose of 20 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a mean dose of 11.7±2.6 mg/week
Number of subjects: 96
Study: 18510807

Group type: EXPERIMENTAL
Intervention: DHA (800 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of DHA and lutein
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 17130504

Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment during the DCCT
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Conventional diabetes treatment during the DCCT
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Combined cohorts (intensive and conventional)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Prior intensive diabetes treatment
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease risk factors (waist-to-hip ratio, smoking, hypertension, hypercholesterolemia)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Mean HbA(1c) levels before enrollment, during the DCCT, and during the EDIC study
Number of subjects: 1205
Study: 15510240

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study: 11516093

Group type: EXPERIMENTAL
Intervention: Lenograstim (glycosylated recombinant human G‐CSF) 5 microg per kg body weight subcutaneously daily from day 8 after starting chemotherapy.
Number of subjects: 112

Group type: COMPARATOR
Intervention: No cytokine
Number of subjects: 112
Study: 9024018

Group type: EXPERIMENTAL
Intervention: Detailed anesthetic risk information
Number of subjects: 334

Group type: COMPARATOR
Intervention: Routine anesthetic risk information (control)
Number of subjects: 334
Study: 8381931

Group type: EXPERIMENTAL
Intervention: Insulin infusion (40 mU.m‐2.min‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Perindopril (converting enzyme inhibitor)
Number of subjects: 7
Study: 3472510

Group type: EXPERIMENTAL
Intervention: Suprapubic catheters
Number of subjects: 60

Group type: COMPARATOR
Intervention: Urethral catheters
Number of subjects: 60
Study: 28949012

Group type: EXPERIMENTAL
Intervention: 200 mg once daily (OD) PF-04965842
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 400 mg OD PF-04965842
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 200 mg twice daily (TD) PF-04965842
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 27573560

Group type: EXPERIMENTAL
Intervention: FOLFOX4/XELOX for 3 months (arm 3 m)
Number of subjects: 3759

Group type: COMPARATOR
Intervention: FOLFOX4/XELOX for 6 months (arm 6 m)
Number of subjects: 3759
Study: 24129358

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 37
Study: 23878319

Group type: EXPERIMENTAL
Intervention: Vaccine-induced T cells targeting ≥3 gag peptides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine-induced T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA-B*27, -B*57 and -B*58:01 alleles
Number of subjects: 0
Study: 20034487

Group type: EXPERIMENTAL
Intervention: Fish oil (1 g/day) for 3 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (without fish oil)
Number of subjects: 83
Study: 18937610

Group type: EXPERIMENTAL
Intervention: Cefotaxime-sulbactam
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 102
Study: 16737416

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg/day for 2 weeks
Number of subjects: 51